Maeda C, Iizuka A, Miyata H, Kondou R, Ashizawa T, Kanematsu A, Watanabe K, Deguchi S, Mitsuya K, Hayashi N, Abe Y, Yamaguchi K, Akiyama Y. Alternative Evaluation of an ELISPOT Assay Using Cytokine Activity as a Novel Parameter.
Anticancer Res 2021;
41:3825-3831. [PMID:
34281842 DOI:
10.21873/anticanres.15175]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Revised: 06/27/2021] [Accepted: 06/28/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM
The enzyme-linked immunospot (ELISPOT) assay is a well-established method used to evaluate the strength of T cell-mediated immune activity, and accepted as a standard functional immunological assay. Cytokine activity is a novel parameter reflecting spot size and intensity, which has not been used in ELISPOT assay before.
MATERIALS AND METHODS
In the present study, from 113 ELISPOT assay data derived from previous clinical trials with dendritic cell vaccines, both spot number count and cytokine activity data for IFN-γ secretion were obtained using an ELISPOT reader. Comparing the new parameter cytokine activity with the existing parameter spot number, the feasibility of cytokine activity was investigated.
RESULTS
There were no significant differences in sensitivity and specificity between spot number and cytokine activity among ELISPOT assay data from CMVpp65 and other antigen peptide-stimulated cytotoxic T lymphocytes.
CONCLUSION
Although cytokine activity is a novel parameter unreported so far, it did not show any advantages in the evaluation T cell immune responses compared to the existing spot number parameter.
Collapse